title: [Gastrointestinal stromal tumours: clinical and therapeutic features. A report of 25 cases].
abstract: OBJECTIVE
  To evaluate the epidemiological clinical features and herapeutic results of gastrointestinal stromal tumour (GIST).
  
  
  METHODS
  This retrospective study concerned 25 cases of gastrointestinal stromal tumour from January 1993 to December 2002. All patients have been operated and the diagnosis of GIST has been confirmed by histological and immunohistochemical study of pieces of resection or biopsies.
  
  
  RESULTS
  Population include II men and 13 women with a mean age of 64 years. Symptomatology was dominated by abdominal pain (54% of cases) and the digestive haemorrhage (46% of cases). A palpable mass has been found in 29% of cases. The tumour was gastric in 17 cases, small intestinal in 6 cases, colic in 1 case and rectal in 1 case. A double gastric localization and small intestinal was found in 1 case. The mean tumour size was 8 cm (1 to 30 cm). A tumour resection has been achieved in 23 cases (96%), extended to neighbourhood organs in 2 cases. The morbidity was 12.5% and there was no operative mortality. Histologically, tumour was of low grade in 10 cases, high grade in 10 cases and unclassified in 5 cases. With a median follow up of 27 months (2 to 108), we observed 4 cases of loco-regional recurrence. Overall survival at 2 years was 74% for the whole population and 35% for the high grade. Independent prognostic factors recovered were the degree of malignancy (p = 0.01) and the local recurrence (p = 0.01).
  
  
  CONCLUSIONS
  The treatment of the GIST is surgical. lymphadenectomy is superfluous. The new oral chemotherapies that inhibits Tyrosine Kinase seems to be promising.
authors.affiliation: Service de Chirurgie Générale A, Hôpital La Rabta, Tunis, Tunisie.
authors.forename: Heikel
authors.initials: H
authors.lastname: Bdioui
authors.forename: Mohamed
authors.initials: M
authors.lastname: Jouini
authors.forename: Hatem
authors.initials: H
authors.lastname: Bouzaiene
authors.forename: Kais
authors.initials: K
authors.lastname: Nouira
authors.forename: Fadhel
authors.initials: F
authors.lastname: Fteriche
authors.forename: Rachid
authors.initials: R
authors.lastname: Ksantini
authors.forename: Faouzi
authors.initials: F
authors.lastname: Chebbi
authors.forename: Montacer J
authors.initials: MJ
authors.lastname: Kacem
authors.forename: Zoubeir
authors.initials: Z
authors.lastname: Ben Safta
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D011505:Protein-Tyrosine Kinases